Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Royalty Pharma plc
High uncertainty: The valuation methods show significant disagreement (>100% spread). Treat the range as a rough guide rather than a precise estimate.
Bear Case (25th pct.)
-42.8% vs price
Base Case (Median)
-26.3% vs price
Bull Case (75th pct.)
82.1% vs price
◇ = Current price | | Bear | Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| DCF (Discounted Cash Flow) | $117.16 | 83.8% | High (40%) |
| PE Comparable | $42.59 | -33.2% | Medium (25%) |
| Growth Trajectory DCF | $175.73 | 175.7% | Medium (20%) |
| Graham Number | $30.31 | -52.5% | Medium (40%) |
| EV/EBITDA | $5.56 | -91.3% | Medium (20%) |
| EV/FCF | $114.99 | 80.4% | Medium (20%) |
| Earnings Power Value | $47.01 | -26.3% | Medium (50%) |
Based on 7 out of 7 methods, RPRX appears fairly valued at the current price of $63.75. The base case fair value of $47.01 implies 26.3% downside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.